Zymeworks Inc. (Nasdaq: ZYME) has appointed Dr. Alessandra Cesano to its board of directors, effective February 8, 2024, succeeding Dr. Kenneth Hillan. Dr. Cesano, with over 25 years of experience in drug development and cancer immunology, brings valuable expertise to the board.
Kenneth Galbraith, Chair and CEO of Zymeworks, welcomed Dr. Cesano, highlighting her insights as the company accelerates its pipeline of biotherapeutics. Her appointment follows the addition of three new directors in 2023.
Dr. Susan Mahony, lead independent director, thanked Dr. Hillan for his service.
Dr. Cesano expressed enthusiasm for joining Zymeworks, aiming to contribute to its mission of advancing oncology therapeutics. With a background in pharmaceuticals and diagnostics, she brings expertise from roles at companies like Amgen Inc. and NanoString Technologies, Inc.
Dr. Cesano’s appointment includes serving on research and development and nominating and corporate governance committees. Mr. Derek Miller has been appointed chair of the latter.
As Zymeworks progresses in its quest for innovative therapies, Dr. Cesano’s addition underscores the company’s commitment to advancing with expertise and dedication.
